A urine test that could foresee kidney danger in the ICU

NCT ID NCT07751913

Not yet recruiting Diagnosis Sponsor: BioPorto Diagnostics Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This trial is testing whether a urine test called ProNephro AKI™ (NGAL) can accurately predict which critically ill adults in the intensive care unit (ICU) will develop moderate to severe acute kidney injury within 48 to 72 hours of admission. The study will enroll 800 adults who are in the ICU or about to be admitted, and will measure NGAL levels in their urine and blood. The goal is to see how well the test performs in terms of sensitivity, specificity, and predictive value, which could help doctors intervene earlier and improve patient care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ProNephro AKI™ (NGAL) urine test
What this could lead to: If accurate, this test could help doctors identify ICU patients at high risk of acute kidney injury earlier, potentially enabling timely interventions and better outcomes.
What could go wrong: The test may not be accurate enough in real-world ICU settings, and results from this validation study may not generalize to all patient populations. There are no direct risks from the test itself, but false results could affect clinical decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY

More trials for these conditions

Other studies related to the condition(s) this trial covers.